Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
2.400
-0.850 (-26.15%)
Jun 6, 2025, 1:45 PM - Market open
Scinai Immunotherapeutics Revenue
In the year 2024, Scinai Immunotherapeutics had annual revenue of $658.00K. Scinai Immunotherapeutics had revenue of $206.00K in the quarter ending December 31, 2024.
Revenue (ttm)
$658.00K
Revenue Growth
n/a
P/S Ratio
3.98
Revenue / Employee
$21,226
Employees
31
Market Cap
2.24M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SCNI News
- 1 day ago - Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. - PRNewsWire
- 7 days ago - Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn - PRNewsWire
- 4 weeks ago - Scinai Announces Annual Financial Results for 2024 - PRNewsWire
- 5 weeks ago - Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases - PRNewsWire
- 2 months ago - Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions - PRNewsWire
- 2 months ago - Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025 - PRNewsWire
- 3 months ago - SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT - PRNewsWire
- 5 months ago - Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences - PRNewsWire